AstraZeneca: Lynparza in China for ovarian cancer
(CercleFinance.com) - On Thursday AstraZeneca announced that China has approved the marketing of Lynparza, the drug it markets with the US group Merck, for the treatment of ovarian cancer, the third most common gynaecological cancer in the country.
The biopharmaceutical group says that the green light from the Chinese authorities concerns first-line maintenance treatment of the disease, in combination with Roche's Avastin, in patients known as "with HRD".
AstraZeneca points out that the five-year survival rate for ovarian cancer is barely 39%, a phenomenon it explains by the fact that over 70% of patients are diagnosed in the late stages of the disease.
Copyright (c) 2022 CercleFinance.com. All rights reserved.